Glenmark Pharmaceuticals has signed a licensing agreement with Swiss based pharma, Helsinn Group for launch of Akynzeo in India and Nepal.

This drug is used to prevent chemo-related nausea and vomiting. It was developed by Helsinn and is at present marketed in European Union, US and other leading markets. Glenmark will have exclusive marketing rights for the drug in India and Nepal and it has received marketing approval from Central Drugs Standard Control Organisation (CDSO), for Akynzeo.

Furthermore, Sujesh Vasudevan, Glenmark President India Formulations, Middle East and Africa stated, “Akynzeo will help Indian patients undergoing chemotherapy and struggling to manage CINV (Chemotherapy Induced Nausea and Vomiting) to address this issue in a much better way.”

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week